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To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent 
neutralizing mAbs against SARS-CoV-2 as therapeutics. However, numerous historical efforts to advance 
antiviral mAbs for the treatment of other respiratory infections have been met with categorical failures 
in the clinic. By investigating the mechanism by which SARS-CoV-2 and similar viruses spread within the 
lung, along with available biodistribution data for systemically injected mAb, we highlight the challenges 
faced by current antiviral mAbs for COVID-19. We summarize some of the leading mAbs currently in 
development, and present the evidence supporting inhaled delivery of antiviral mAb as early 
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1. Introduction  
Severe Acute Respiratory Disease Syndrome Coronavirus 2 (SARS-CoV-2), the etiologic agent of 
coronavirus disease 19 (COVID-19), has caused a global pandemic at a scale not seen for nearly 100 
years. In response, historic efforts bridging across industry and academia have advanced potential 
vaccines and therapeutics into the clinic at a pace never before witnessed.   
SARS-CoV-2 can be classified under a group of viruses that cause acute respiratory infections 
(ARIs), characterized by their respiratory tropism and predominant spread within the airways until 
infection of the deep lung. Thus, we believe there are important lessons to be gained from studying 
efforts in developing vaccines and therapeutics for ARIs. Despite the large number of common ARIs, 
including influenza, respiratory syncytial virus (RSV) , parainfluenza virus (PIV), metapneumovirus, 
rhinoviruses and seasonal coronaviruses, there remains no vaccine or treatment for virtually any ARIs, 
with the exception of influenza.  Even with influenza vaccines, the efficacy remains modest, ranging 
from a low of 19% to a high of 60% between 2009 and 2019 in the U.S.[1].  While the poor efficacy is 
frequently attributed to the difficulty in accurately predicting which influenza strains will circulate in 
different communities during an upcoming flu season [2], the actual reasons are likely multifold.  There 
are important subpopulations that generally do not respond well to vaccines, including infants, the 
elderly, and immunocompromised adults. For instance, infants 1-2 months old have been shown to only 
rarely produce a humoral response against the viral surface glycoproteins in response to vaccination, in 
contrast with older children [3]. This finding is in line with studies of antibody titers observed in children 
under 6 months who are hospitalized with RSV infection, among whom fewer than 50% develop a 
neutralizing antibody response [4].  Current vaccination also results in rapid intraseason waning of 
protective immunity, with effectiveness declining ~16% every 28 days [5], possibly due to decline of 
influenza vaccine–induced human bone marrow plasma cells [6].  It is encouraging that interim analysis 












against symptomatic disease during the immediate weeks following the second (booster) injection, 
compared to saline control.  The efficacy of another vaccine (AstraZeneca/Oxford) was ~62% compared 
to the meningococcal conjugate vaccine control.  In all cases, the durability of the immunity will only be 
revealed in the coming months and years.  Even with highly effective vaccines, there will likely be 
patient subgroups who fail to benefit comparably (e.g. immunocompromised adults) as well as those 
who are not vaccinated and become sick.  Thus, there will almost certainly be a strong demand for 
effective treatment options for COVID-19 in the coming years.  
Among the various potential therapeutic interventions, monoclonal antibodies (mAb) represents 
one of the most promising classes of molecules, due to their longstanding track record of safety in 
humans, their exceptional specificity to the virus that minimizes risk of off-target effects, and their 
ability to coordinate the immune defense in the fight against infection.  Technological advances over the 
past two decades in sequencing and single cell screening, as well as manufacturing, has positioned mAbs 
to quickly respond to the COVID-19 pandemic.  In this review, we first highlight important 
pathophysiology associated with SARS-CoV-2, protective functions of antibodies in mucus, and some of 
the leading mAb under development for SARS-CoV-2.  We then examined the track record of mAbs that 
have been advanced to address other ARIs in the past and used the insights to identify opportunities 
where the potential efficacy of antiviral mAb for COVID-19 can be improved. 
 
2. Mechanism of spread of many acute respiratory infections (ARIs)  
2.1. Predominant apical infection and shedding 
The human respiratory system can be broadly divided into (i) the upper respiratory tract (URT) 
encompassing the nasal cavity and pharynx, (ii) the lower respiratory tract (LRT) that begins at the 
trachea and extends all the way down to bronchioles, and (iii) deep lung, i.e. the alveolae. Within the 












that lines the conducting airways, and a specialized epithelium that lines the alveolus. The alveolar 
epithelium is dominated by pulmonary alveolar type I (AT1) cells, which are covered by no more than 
~200 nm of liquid (termed epithelial lining fluid) [7] and make up more than 95% of the alveolar surface 
area, where they play a central role in gas exchange [8]. In contrast, the airway epithelium possesses a 
unique morphology and function, including a polarized epithelium with tight junctions, formation of 
cilia, and the secretion of mucins that form a viscoelastic airway mucus (AM) gel overlaying the 
epithelium. These cellular features critically impact how viruses infect and propagate within the lung but 
cannot be accurately recapitulated by in vitro cultures of airway epithelial cells fully submerged in liquid 
media.  
The most rigorous model capturing this complex pulmonary physiology is created by culturing 
human nasal or tracheobronchial epithelial cells, collected from airway brushings or from cadaver 
airway tissue, on semi-permeable membranes for at least 20-25 days. This model, commonly referred to 
as well-differentiated human airway epithelial (WD-HAE) culture, exposes cells to air in the apical 
compartment but provides essential nutrients through direct contact with the culture media in the basal 
compartment. This air-liquid interface culture results in a polarized, well-differentiated, ciliated airway 
epithelium with a secreted mucus layer [9-11].  
Unlike studies using submerged liquid cultures with non-polarized epithelial cells [12], studies 
using WD-HAE cultures revealed that many viruses responsible for common ARIs almost always 
exclusively infect via the apical (luminal) side of the airway epithelium, with little to no productive 
infection when viruses are introduced into the basal (serosal) compartment (Figure 1). More 
importantly, infected cells appear to predominantly, if not exclusively, shed progeny viruses back into 
the apical compartment (i.e. into AM secretions), with limited to no shedding of virus into the basal 
compartment. For example, influenza infects WD-HAE cultures apically, and almost exclusively sheds 












consistent with prior findings that Rab11, a GTP-binding protein related to endocytic recycling, is both 
crucial for the budding of influenza and is exclusively trafficked to the apical membrane in polarized 
epithelial cells [17, 18]. Similar apical infection and shedding has been confirmed for other common 
viruses responsible for common ARIs, including RSV [19-23], PIV [24], and the betacoronavirus HKU1 
[25].  
SARS-CoV-1 and SARS-CoV-2 bind the same receptor for cellular entry: Angiotensin-converting 
enzyme 2 (ACE2). Similar to influenza and RSV, SARS-CoV-1 only productively infects WD-HAE cultures 
when the virus is inoculated apically, with no appreciable infection when the same amount of virus is 
inoculated basally (Figure 1) [26].  Equally importantly, there is ~1,000-fold greater virus shed into the 
apical compartment relative to the basal compartment [26]. The near exclusive apical infection and 
shedding of SARS-CoV-1 is consistent with the trafficking of ACE2 to the apical membrane of the human 
airway epithelium in vivo and in WD-HAE cultures in vitro [26-28]. Given that SARS-CoV-2 binds the same 
ACE2 receptor for cellular entry, it is not surprising that SARS-CoV-2 undergoes the same preferential 
apical infection and shedding [26-28], and that apical infection of polarized cells in vitro leads to 
substantially more virus than basolateral infection [29]. Immunofluorescent staining of airway biopsy 














Figure 1.  Infection and spread of SARS-CoV GFP infection in HAE over time after apical or basolateral inoculation. HAE were 
inoculated via the apical (A, C, E, G, and I) or basolateral (B, D, F, and H) compartments with SARS-CoV GFP and GFP-positive 
cells and assessed over time (1 to 5 days post-infection). Apical inoculation leads to progressive increase in GFP fluorescence 
over time, with significant infection after 40 hours (C) and maximum fluorescence after 90 hours (G). Basolateral infection is not 
effective, only a small proportion of cells are GFP positive 68 hours after infection.  Results are representative of three repeats. 
Adapted from [26]  with permission from American Society for Microbiology, Journal of Virology. 
 
2.2. Apical infection and shedding consistent with clinical features of ARIs 












Based on studies using WD-HAE cultures, apical shedding of virus and subsequent reinfection 
appears to be the primary route responsible for the spread of influenza and RSV from the URT to the 
LRT, before eventually infecting the deep lung. In other words, the infection does not spread to the deep 
lung either through the systemic circulation or by direct cell-to-cell transmission. This stepwise 
propagation of the infection from the URT to LRT and, finally, the deep lung is consistent with the clinical 
hallmarks of common ARIs.  Infections with influenza and RSV first result in symptoms in the URT such as 
cough, congestion, and sore throat. These symptoms create opportunities for molecular diagnosis of the 
infection while the infection is still primarily in the URT, before the virus extensively infects the LRT and 
finally the deep lung.  There is generally at least several days between the onset of URT symptoms and 
virus-induced bronchiolitis and pneumonia that necessitates medical attention, including hospitalization 
in a small fraction of individuals, primarily those with immature or compromised immune systems such 
as infants, immunocompromised adults, and the elderly. This time frame between the first development 
of symptoms and progression to severe disease, which varies depending on the virus, represents a prime 
window of opportunity to prevent LRT infections and pathologies, as exemplified by the current 
guidelines for prescribing antivirals such as oral oseltamivir, approved by the FDA for treatment of acute 
uncomplicated influenza within 2 days of onset of illness.   
This mechanism of apical shedding and propagation of many ARIs is also consistent with current 
standards of diagnosing these infections using either nasal or nasopharyngeal swabs, rather than blood 
sampling. Indeed, nasopharyngeal swab is the collection method for the commonly used respiratory 
pathogen panels, tests used to simultaneously diagnose or rule-out dozens of respiratory pathogens, 
including the four seasonal coronaviruses, adenovirus, metapneumovirus, influenza A and B, 
parainfluenza, RSV, rhinovirus, and bacteria such as Chlamydia pneumoniae, Mycoplasma pneumoniae, 
Bordatella pertussis, and others [31, 32]. In contrast, analysis of blood from patients infected with ARIs 












MPV [35]. Detectable titers of infectious viruses generally only start entering the systemic circulation 
when the infection has reached the deep lung, where viruses can more easily penetrate the much-
thinner epithelial lining, and where infection-induced inflammation can more readily compromises 
epithelial barrier function [36-38]. 
 
2.2.2. SARS-CoV-1 and SARS-CoV-2 
Boucher and colleagues conducted RNA mapping of ACE2 expression in various regions 
throughout the respiratory tract to identify key sites for SARS-CoV-2 infection [36]. Their quantitative 
assessment revealed relatively high ACE2 expression in the trachea and bronchi, lower ACE2 expression 
in the bronchioles and alveoli, and relatively uniform expression of Transmembrane Serine Protease 2 in 
both the URT and LRT [36]. Differential ACE2 expression correlates with greater infectivity of SARS-CoV-2 
in polarized cultures of cells from different parts of the respiratory tract [36]. These findings are 
consistent with the hypothesis that SARS-CoV-2 infections first establish in the nose and URT – sites that 
are most exposed and most susceptible to transmission – followed by spread through the LRT before 
eventually infecting the deep lung. Apical shedding and propagation also explains why clinical reports to 
date indicate relatively limited viremia of SARS-CoV-2 (i.e. infectious viruses in the blood) before the 
disease has progressed to more severe infection, hyper-inflammation, and lung injury to the more 
fragile alveoli [36]. 
For SARS-CoV-1, a summary WHO report [39] described the incubation period as typically being 
from 2-7 days, potentially as long as 10 days after exposure. Then, ~3-7 days following the first 
development of symptoms, a lower respiratory phase begins, including dyspnea that sometimes leads to 
hypoxia and ultimately requires mechanical ventilation in 10-20% of infected patients [39]. Thus, the 
clinical course of SARS mirrors our current understanding of the pathogenesis of ARIs, in which early 












to the LRT and the deep lung. Given that SARS-CoV-2 targets the same ACE2 receptor, it is not surprising 
that the clinical presentation and progression of COVID-19 is also quite similar.  There is generally a 
substantial lag between the first symptoms of SARS-CoV-2 infection in the URT to when these patients 
begin to experience dyspnea (5-7 days after symptoms), and a delay of ~9.5 days between symptoms 
and ICU admission [40-42]. Thus, the first few days following the development of symptoms represents 
a crucial window for interventions aimed to prevent progression to LRT disease. Case series and contact 
tracing studies following patients with COVID-19 have suggested an incubation period that varies across 
individuals but is typically ~6 days between exposure and the development of symptoms [43]. 
 
3. Antibody function in airway mucus (AM)  
 Antibodies play a major role in the body’s adaptive immunity to infections.  Indeed, greater 
levels of anti-flu mAb in the nasal mucosa have been shown to be correlated with more rapid 
elimination of the virus in humans [44]. Nearly all vaccines seek to elicit effective antibody titers against 
viruses of interest; passive immunization or therapy with antiviral mAbs seek to bypass the need for the 
immune system to learn to produce neutralizing antibodies by directly producing and delivering the 
antibodies needed.  Given the apical infection and shedding of SARS-CoV-2 that concentrates the viruses 
in the AM overlaying the respiratory epithelium, it is imperative to understand the characteristics of 
endogenous antibodies in AM, particularly their functions in blocking the spread of the infection, in 
order to ensure we can recapitulate these essential functions through either vaccine-elicited antibody 
response or administered mAb. 
 












Unlike the gastrointestinal tract, where sIgA is the predominant antibody isotype, and unlike 
cervicovaginal mucus lining the female reproductive tract where IgG is the predominant antibody, there 
is an abundance of both sIgA and IgG in the AM lining the airways in the URT and LRT.  
IgA has two subclasses, IgA1 and IgA2, and is the classic antibody isotype associated with 
mucosal protection. Dimeric IgA (dIgA) is produced by plasma cells in the lamina propria and comprises 
two IgA molecules linked by a J-chain protein. The dIgA is then bound by secretory component (SC), a 
protein found in the plasma membrane on the basolateral surfaces of a sub-population of mucosal 
epithelial cells. This dIgA-SC complex on the plasma membrane is then transcytosed and released into 
the AM as secretory IgA (sIgA) [45, 46]. While ~90% of IgA in the systemic circulation is monomeric, 
~50% of IgA in AM is dimeric, i.e. sIgA [47, 48].  Since current manufacturing technologies are unable to 
produce and deliver large quantities of sIgA, the rest of this review will focus on the role of IgG in 
mucosal protection. 
 Abundant quantities of IgG have been found in AM and nasal lavages [49] , including all four 
subtypes of IgG. In general, the ratio of IgG to sIgA in the range of 1:1 to 1:3 [50, 51]; early work by 
Deuschl and Johansson showed that comparable levels of both IgG (~0.12 mg/mL) and sIgA (~0.14 
mg/mL) are detected in tracheo-bronchial lavages; the actual concentrations in undiluted AM are most 
likely substantially higher, possibly exceeding 1 mg/mL.  Similarly, there are comparable levels of total 
IgG (~240 µg/mL) and IgA (~337 µg/mL) in induced sputum [52]. 
At the gas-exchange surface of the alveoli, the barrier to the blood is thinnest; thus, a fraction of 
immunoglobulins in the blood can enter via passive transudation [53].  Along the conducting airways, 
plasma cells associated with local lymphoid tissue can directly secrete immunoglobulins [54].  IgA2 
represents ~20% of total serum IgA, but ~30% of total lung IgA [55]; these differences reflect 
considerable local production of sIgA in the lung, with some estimates suggesting >80% of sIgA in 












are also located in the bronchial mucosa [56, 57]. By analyzing the ratio of albumin to different IgGs in 
induced sputum, it has been estimated that local plasma cell production accounts for over 50–60% of 
the IgG1 and IgG2 in the lung, and as much as ~80–90% of the IgG3 and IgG4 [58].  
 
3.2.  Mechanisms of antibody-mediated protection 
3.2.1. Neutralization 
The Fab domains of IgG can bind with exquisite specificity to epitopes on the viral surface [59]. 
When the antibodies bind viral epitopes that are responsible for binding the host cell receptor, IgG can 
directly inhibit cellular entry and infection [60]. In addition, some virus-bound antibodies can interfere 
with cellular processes essential for productive infection without interfering with viral entry into the 
cells. Collectively, antibodies that can directly neutralize the virus without the aid of other immune cells 
or immune factors are referred to as neutralizing antibodies. Unsurprisingly, following vaccination, the 
generation of neutralizing antibodies is one of the best predictors of protection against future infections 
[61]. Nevertheless, not all induced antibodies produced in response to vaccination or infection can 
neutralize the virus directly; instead, the Fc domain of virion-bound IgG can facilitate other effector 
functions that enhance protection against viral infections. 
 
3.2.2. Classical Fc effector functions 
In addition to neutralization, IgGs in the lung can facilitate effector functions such as 
complement activation, opsonization, and antibody-dependent cellular cytotoxicity (ADCC) [62, 63]. 
When IgG has opsonized a target pathogen, they can initiate complement-dependent cytotoxicity (CDC) 
[64], a chain of events that begins when the Fc of antibodies bound to a pathogen or pathogen-infected-
cell attract complement protein C1q, leading to a cascade of events that ultimately cause direct 












and C5a, potent anaphylatoxins that mediate vasodilation, chemotaxis of leukocytes, and other 
inflammatory effector functions that aid the innate response to infection [62].  
ADCC is a similar process that is initiated when IgG binds viral proteins on an infected cell’s 
surface. However, instead of interacting with C1q, the Fc domain of the attached IgG interacts with Fc 
receptors on leukocytes, inducing the release of cytotoxic cargo that directly kill the infected cell [62]. 
For example, the infusion of anti-simian immunodeficiency virus antibodies to animals infected with SIV 
demonstrated a subsequent decrease in viremia with a profile suggesting that the ADCC led to direct 
killing of virus-infected cells [65]. In the lung, alveolar macrophages carry out ADCC [66]: ~25% of 
alveolar macrophages can bind IgG3, and ~10% bind IgG4, with little binding IgG1 or IgG2 [67]. 
Interestingly, IgG can interact with lung-specific surfactant protein A (SP-A) to enhance some of its 
effector functions. For instance, SP-A bound to IgG-opsonized pathogens enhances phagocytosis relative 
to opsonization with IgG alone [68]. Importantly, IgG that are paired with SP-A are still capable of 
forming immune complexes and binding to C1q to initiate the classical complement cascade [63, 68].  
 
3.2.3. Fc effector functions specific to mucus: muco-trapping via mucin-crosslinking 
A recently discovered yet little recognized effector function of virus-specific IgG is to crosslink 
viruses to the mucin mesh [69-74], leading to their immobilization in AM (Figure 2). By trapping viruses 
in AM, shed progeny viruses are unable to readily diffuse through AM to spread the infection within the 
lung.  Trapped viruses are then quickly eliminated from the lung through natural mucociliary or cough-
driven clearance, thereby offering a mechanism of direct physical clearance of viruses from infected 













Figure 2. Proposed mechanism of antibody (Ab)-mediated trapping of viruses in mucus. Schematic showing (a) herpes simplex 
virus (HSV) readily penetrating native cervicovaginal mucus (CVM) with little-to-no endogenous HSV immunoglobulin G (IgG), 
and (b) anti-HSV IgG trapping HSV in CVM by multiple transient, low affinity bonds in mucins. By forming only short-lived, low-
affinity bonds with mucus, free Ab, such as IgG, are able to diffuse rapidly through mucus and bind to viruses. As IgG molecules 
accumulate on the virus surface, they form multiple low-affinity bonds between the virus and mucus gel. A sufficient number of 
these transient low-affinity bonds ensure viruses are effectively trapped in mucus at any given time, thereby reducing the flux 
of infectious virions that can reach target cells.  Adapted from [69] with permission from Springer Nature. 
 
This unique mechanism of mucosal antibody protection was long overlooked because the 
affinity of individual antibody molecules to mucins was thought to be far too weak to directly crosslink 
pathogens to mucins. Indeed, the diffusion coefficient of IgG and IgA antibodies in human mucus is only 
slowed ~10% compared to in water[75, 76] , indicating that any bond between antibodies and mucins is 
exceedingly transient (seconds or fractions of a second) and readily broken up by thermal excitation 
[75]. Nevertheless, multiple IgGs can bind the same virus or bacteria, and the resulting array of bound 
antibodies on any individual pathogen/antibody complex can form multivalent interactions with the 
mucin mesh, providing avidity sufficient to trap individual pathogens nearly permanently.   
This concept was first illustrated with herpes simplex virus (HSV), where HSV-specific IgG 
mediated effective trapping of HSV in human cervicovaginal mucus and protected against vaginal HSV 
transmission in mice [69]. Extension of this concept to AM was recently illustrated with influenza virus, 
whose mobility were directly correlated with endogenous influenza-binding antibodies in AM, even for 













Figure 3. Ebola pseudovirus distribution in the mouse lung airways. A–D, Representative transverse 50-µm-thick frozen tissue 
sections showing the distribution of Ebola pseudovirus in the mouse trachea treated with phosphate-buffered saline (PBS) (A, 
B) or ZMapp (C, D). Red corresponds to Ebola pseudovirus, and blue corresponds to 4',6-diamidino-2-phenylindole (DAPI)-
stained cell nuclei. Arrows indicate the inner lining of the trachea. E, Quantification of Ebola pseudovirus signal in mouse 
trachea treated with PBS (control) or ZMapp compared with blank tissue. Data represent n = 3 mice per group with, on average, 
10 tissue sections quantified per mouse. Error bars represent standard error of the mean. * indicates a statistically significant 
difference (P<0.05) based on a two-tailed Student’s t-test assuming unequal variance.  Adapted from [71] with permission from 












IgG can effectively purge non-infectious Ebola virus-like particles from the lungs of mouse within just 30 
mins of intranasal mAb dosing [71] (Figure 3). Unpublished work from our group suggests nebulized 
muco-trapping IgG into RSV-infected lambs can effectively reduce RSV infectious viral load in the lung to 
near non-detectable levels within just 3 days, even when given at near peak viral titer in the lung, 
leading to greatly reduced bronchiolitis in the treated animals. 
The crosslinking of IgG-Fc with mucins appears to be mediated by specific N-glycans on IgG-Fc; 
removing either the Fc or the N-glycans greatly reduced muco-trapping [69]. There is likely a goldilocks 
range for the affinity between individual IgG and mucins that optimizes this effector function [72]: if the 
affinity is too weak, many IgG molecules must be bound to an individual pathogen to generate sufficient 
avidity to trap. In contrast, if the affinity is too strong, IgG lose their ability to undergo rapid diffusion in 
mucus and quickly accumulate on the pathogen surface. The ability for Fab domains on IgG to bind 
viruses with high specificity, coupled with IgG-Fc that interact with mucins, effectively transform AM 
overlaying the airway epithelium into a potent adhesive filter that can quickly clear viruses from the lung 
with exceptional specificity and potency [72]. 
 
4. mAb against SARS-CoV-2 
 In this section we summarize the current Ab development efforts against SARS-CoV-2, including 
information about their epitopes and also highlight some other approaches using non-Ab scaffolds 
including results from animal models where applicable. Further information about the current status of 
SARS-CoV-2 Abs in clinical trials is also discussed.  
4.1. Spike protein as antiviral mAb target  
Coronaviruses infect host cells by engaging key host-cell receptors through its trimeric Spike (S) 
glycoprotein. A monomer of S glycoprotein of SARS-CoV-2 (~180kDa) has two subunits: (i) S1, which 












host-cell receptors, and (ii) S2, which contains a fusion peptide (FP), heptapeptide repeat sequences 
(HR1, HR2), a transmembrane domain (TM) and a cytoplasmic domain, promotes fusion of the viral and 
cellular membranes [78, 79].  The S protein exists as a trimer on the viral envelope. Cryo-EM imaging of 
SARS-CoV-1 reveals each virion possesses ~50-100 spike trimers, with an average distance between 
spikes of ~15 nm [80]. The sequence of SARS-CoV-2 is about 70% homologous to SARS-CoV-1, and the 
two share about 80% sequence identity in the RBD and the requirement of ACE2 for entry [81-84], 
suggesting SARS-CoV-2 may have similar a presentation of spikes on the viral surface.  
 Structural characterization of the SARS-CoV-2 S protein by Cryo-EM [81, 85, 86] shows that each 
of the S1 on the trimeric spike can independently assume either an open (“up”) conformation that 
exposes the RBD, or in the closed (“down”) conformation, whereby the surface of RBD that engages 
ACE2 is buried inside the trimer and thus not accessible for receptor binding (Figure 4). The binding of S 
protein to ACE2 has been extensively characterized [81, 85, 87-91]. Binding of host ACE2 to exposed RBD 
leads to a 3-up conformation that is unstable, leading to S1 shedding and S2 refolding to promote 
membrane fusion [81, 92]. In structural studies, the proportion of S1 RBD in the up conformation for 
SARS-CoV-1 prefusion spikes (i.e. 1-up or 2-up) in both unbound and ACE2-bound state was found to be 
about 55%, but almost no spikes had 3-up conformation, and the 2-up conformation was the most 
common [93, 94]. Trypsin cleavage of SARS-CoV-1 spike results in about 95% of spikes in the up 












Figure 4. Conformations of SARS-CoV-2 spike protein. A) Schematic depicting S protein bound to ACE2 receptor, including S1 
and S2 subunits. B) Top and side view of S protein with one S1 subunit in up conformation. C) Movement of the S1 subunit 
makes it possible for spike protein to assume conformations where alL S1 units are down, one S1 unit is up, two S1 units are up, 
or all S1 units are up. Reproduced from [95] with permission from ACS, https://pubs.acs.org/doi/10.1021/acs.jpclett.0c01431. 
Further permission related to the material excerpted should be directed to the ACS.  
 
Not surprisingly, given the structural homology between their spike proteins, some SARS-COV-1 
binding mAbs also bind SARS-CoV-2, including CR30222 [96, 97] , S309 [98] and even mAbs isolated from 
B-cells of some patients who recovered from SARS-CoV-2 infection [99].  While a majority of potent 
neutralizing mAbs bind the RBD and block ACE2 binding, neutralizing mAbs can also bind other parts of 
the spike, including NTD or the S2 subunit. The precise mechanisms for how non-RBD binding mAbs can 
effectively neutralize SARS-CoV-2 remain unclear. While ACE2 can only bind RBD when at least one S1 is 
in the up conformation, structural alignment of CR3022–SARS-CoV-2 RBD suggests that the binding of 
CR3022 to RBD can be sterically hindered if the RBD on an adjacent protomer adopted a down 












SARS-CoV-2, depending on the epitope availability resulting from dynamic fluctuation of the S protein. 
Indeed, there are significant differences in neutralization potency of RBD binding mAbs with similar 
binding affinity [99, 100].  
 
4.2. Human mAbs isolated from convalescent blood 
Since the onset of the pandemic, there has been an unprecedented global effort spanning 
across large pharma, startup companies, and academic researchers to discover and engineer mAbs 
against SARS-CoV-2 that can potently neutralize the virus. Much of this effort has centered on isolating 
potent neutralizing Ab against SARS-CoV-2 from B-Cells of patients who have recovered from the 
infection [98-114], with the notion that their recovery may be at least partially attributed to protection 
offered by specific antibodies produced by their immune system. More importantly, unlike in vitro 
affinity maturation by phage/yeast display that may create unnatural Abs with poor stability and 
pharmacokinetics in a complex biological environment, B-cell secreted Abs are already pre-selected for 
stability and activity. The COVID-19 pandemic has shown that, with the advances in single cell 
sequencing, deep sequencing, microfluidics, and cell sorting that have occurred over the past 2 decades, 
it is now possible to isolate individual clones of potent neutralizing mAb on the order of days to weeks.    
To isolate mAbs that can effectively neutralize SARS-CoV-2, the most frequently exploited 
approach is to identify B-cells with B-cell receptors (BCR) that bind the RBD fragment of the S protein 
with high affinity, since such binding likely sterically inhibits interactions between RBD and ACE2.  In 
good agreement with this expectation, many of the isolated mAbs [98-114] bind S proteins with 
picomolar affinity. For example mAbs C121, C144, and C135 isolated by the Nussenzweig group have 
respective IC50 values of 1.64, 2.55, and 2.98 ng/ml against SARS-CoV-2 [99].  This in turn translates to 
exceptional neutralization potency against SARS-COV-2 [115]: many of them possess IC50 below 15 












Table 1. Select human or humanized mAb against SARS-CoV-2. 
mAb Group Antigen IC50 (pseudovirus) IC50 (live virus) Refs 












COV2-2196 Crowe S-protein 0.7 ng/ml 15 ng/ml [100] 
REGN10933 
REGN10987 






P2C-1F11 Zhang RBD 30 ng/ml 30 ng/ml [113] 
B38 Liu RBD - 177 ng/ml [112] 
ADI-56046 Walker S-Protein 40 ng/ml 76 ng/ml [114] 
2-15 Ho S-Protein 5 ng/ml 0.7 ng/ml [104] 
CT-P59 Celltrion RBD  8.4 ng/ml [116] 
CB6 Junshi Bioscience RBD 33.3 ng/ml 36 ng/ml [109] 
CC12.1 Burton S-Protein 19 ng/ml 22 ng/ml [107] 
BD-368-2 Xie S-Protein + RBD 1.2 ng/ml 15 ng/ml [103] 
 
Despite highly varying neutralizing titers among patients’ convalescent plasma [117], potent 
neutralizing Ab was isolated in vast majority of patients [99].  Interestingly, many of the most potent 
mAbs appeared to form with only modest levels of somatic hypermutation, as reflected by the small 
number of mutations compared to their closest germline sequences [118, 119]. Very little somatic 
hypermutation or clonal B cell expansion was observed in five patients for up to 2.5 months after SARS-
CoV-2 transmission [106]. The precise immunological mechanisms responsible for the limited somatic 
hypermutation or clonal expansion are unclear; it may be possible that the high affinity of near-germline 
IgG antibodies against SARS-CoV-2 simply limits antigen access to the germinal center. Nevertheless, the 
limited need for somatic hypermutations to generate high affinity neutralizing mAbs against SARS-CoV-2 
is consistent with the highly comparable neutralization potencies (2-10 ng/mL range) among the 
numerous mAbs generated independently by different groups.   
Beyond isolating mAbs from recovered patients, it is possible to employ other methods to 
isolate human/humanized mAbs against SARS-CoV-2.  One such approach is Regeneron’s high-












and VelociGene® technologies [120]. The same platform was used to generate Regeneron’s anti MERS-
CoV mAbs, REGN 3051 and REGN 3048, that possess affinities between 40-48 pM. Most recently, 
Regeneron applied its VelocImmune® mice and sequencing of B-cells from convalescent COVID-19 
patients to isolate potent SARS-COV-2 neutralizing antibodies [105]. The isolated mAbs had affinities for 
spike proteins between 37.1 to 42.8 pM, and IC50 against live virus of 37.4 to 42.1 pM (5.61 to 6.30 
ng/mL). A cocktail of two antibodies, REGN10933 and REGN 10987, is currently in clinical trials for 
treating hospitalized (NCT04426695) or ambulatory (NCT04425629) adult patients. Other humanized 
mouse technologies for isolation of monoclonal exist, and a review of different monoclonal antibodies 
isolated with these platforms can be found elsewhere [121]. 
A number of non-RBD binding yet neutralizing mAb have also been described [98, 104, 110]; 
these mAbs do not block ACE2 binding, but still neutralize infection. For example, in a study by Liu et al, 
NTD binding mAbs 2-17, 5-24 and 4-8 had respective IC50 values of 7, 8 and 9 ng/ml, and mAbs 2-43 and 
2-51 that bind neither RBD nor NTD had IC50 values of 3 and 7 ng/ml  for neutralization of live SARS-CoV-
2 virus infection, comparable to some of the best RBD-binding mAbs [104]. Although many of the mAbs 
that block ACE2 interaction are only able to bind the RBD on S proteins in the up conformations, other 
non-RBD-binding mAb are also able to bind S in the down conformation [99, 100, 104, 105]. 
 
4.3. Non-human mAb 
4.3.1. Nanobodies   
Camelid sera contain unique heavy chain antibodies (VHH) that do not incorporate a light chain 
[122]. Similarly, cartilaginous fishes have heavy-chain antibodies (IgNAR) from which antigen domain 
antibodies VNAR can be obtained [123]. These antigen binding domains, commonly referred to as single-
domain antibodies or nanobodies, can be expressed recombinantly in non-mammalian cultures, and do 












offer potential advantages over traditional IgG-based mAbs, they also pose some limitations, including 
short serum half-life, an inability to facilitate effector functions, and immunogenicity. Some of these can 
be addressed by the addition of an IgG Fc, which would necessitate production using mammalian 
cultures. Nanobodies are currently in clinical trials for a diverse array of human diseases [124]; 
Caplacizumab was the first nanobody approved by the FDA in 2019 [125]. Clinical development of ALX-
0171, an inhaled nanobody against RSV, was recently discontinued [126]. Potent nanobodies have been 
developed against SARS-CoV-2 [127-132], with some like mNB6tri [130] possessing picomolar IC50s (2.3 
ng/ml) in live SARS-CoV-2 infection assays. 
 
4.3.2. Other biological scaffolds  
Other scaffolds have also been used to develop potent inhibitors of SARS-CoV-2 infection. Linksy 
et al. [133] and Cao et al. [134] developed molecules by de novo design using helices capable of binding 
RBDs on S proteins; the best molecule, LCB1, had IC50 of 24pM (0.16ng/ml) in live SARS-CoV-2 infection 
assays [134].  Human VH domain based molecules (VH-Fc) capable of neutralizing SARS-CoV-2 infection 
have also been developed by various groups [133, 135, 136].  Ab8 had an IC50 of 40ng/ml for 
neutralization of live SARS-CoV-2 [133]. 
 
4.3.3. ACE2 decoys and derivatives 
Viral escape mutants can readily develop against specific mAb, with escape mutants still 
retaining ACE2 binding [137].  Thus, in contrast to mAb discovery or de novo design, a number of 
research groups have focused on developing ACE2 decoys, including recombinant ACE2-Fc (fusion of 
ACE2 and IgG1-Fc).  ACE2-Fc can block infections by SARS-CoV-1 [138] and SARS-CoV2 [136, 139].  
Nevertheless, the potency of recombinant WT ACE2 is 2-3 logs worse than the best neutralizing mAb. To 












structural knowledge and screening of mutant libraries [140-142]. Some of these mutants exhibit 
significantly improved affinity to SARS-CoV-2 RBD, with neutralization potency that rivals some of the 
human mAbs. 
Other studies have attempted to increase the valency of ACE2 or ACE2 mutants by linking them 
to a trimerization domain instead of an IgG1 Fc to generate mutant ACE2 trimers, demonstrating, in 
some cases, better potency than ACE2-Fc dimers [143, 144]. Another approach linked an NTD binding 
mAb to ACE2-Fc, resulting in ~100 fold improvement over ACE2-Fc in binding and neutralization [145].  
 
4.4. Efficacy in animal models to date 
Alongside the current intense efforts for SARS-CoV-2 mAb discovery, many groups have been 
exploring suitable animal models for COVID-19.  Various animal models have been developed for SARS-
CoV-2 infection studies, including the use of transgenic mice with hACE2, Syrian hamsters, ferrets, and 
non-human primate models in rhesus macaques, cynomolgus macaques, and African green monkeys. 
Several reviews have recently summarized these and other animal models and findings [146, 147].  
A number of studies have focused on the use of mAb for passive immunoprophylaxis, given to 
animals prior to viral challenge to assess protection against infection.  Viral RNA copy numbers and 
infectious virus titers were reduced by 4-6 logs in golden Syrian hamsters intraperitoneally administered 
a dose of 1.5 mg/kg of the mAb 2-15, 24 hours prior to intranasal challenge with 105 PFU of SARS-CoV-2 
[104].  In Syrian hamsters given 0.9mg/kg – 16.5mg/kg of the mAb CC12.1, 24 hours prior to intranasal 
virus challenge, reduced viral RNA copy numbers by ~2-3 logs [107].  
A small number of in vivo studies have assessed both prophylaxis and therapeutic efficacy. In 
rhesus macaques, viral titers from throat swabs were reduced by 6 logs and 3 logs in animals receiving 
50 mg/kg of CB6(LALA) intravenously 24 hours prior-to or 1 and 3 days after infection, respectively 












COV2-2196 and mAbCOV2-2130 demonstrated 3 logs reduction in lung viral titers at 200 µg/mouse 
administered 24 h before or 12 h after intranasal challenge with 4 × 105 PFU SARS-CoV-2 [100]. 
Additionally, there were 2-3 logs reduction in viral RNA copies in nasal swabs of macaques dosed with 
50 mg/kg mAb COV2-2196 or mAb COV2-2381, 3 days before challenge with 1.1 × 104 PFU SARS-CoV-2 
[100]. Greater prophylactic efficacy vs. therapeutic efficacy was also observed with other studies.  In 
hACE2 transgenic mouse, 20 mg/kg injection of the mAb BD-368-2 reduced 105 TCID50 SARS-CoV-2 lung 
viral titers by 6 and 3 logs when given 24 h before and 2h after infection, respectively[113]. Similarly, 
again using hACE2 transgenic mouse, 25 mg/kg mAb B38 or mAb H4 given intravenously 12 h after 
intranasal infection with 5x105 TCID50 COVID19 virus reduced lung viral RNA copies by ~3 logs, with 
reduced lung damage [99]. 
 
4.5. Anti-SARS-CoV-2 mAbs in the clinic 
Due to the considerable costs to advance a mAb into the clinic, only a small fraction of the 
discovered mAbs described above have reached the clinic over the first 6 months of the pandemic (as of 
Nov 2020).  A number of other human mAbs, nanobodies, and ACE2-decoys will likely initiate clinical 
studies over the next 6 months. 
The first clinical trial of a mAb to treat COVID-19 was Eli Lilly mAb LY-CoV555 (partnered with 
AbCellera) initiated on 5/28/2020 (NCT04411628). It is a human IgG1 targeting the spike protein derived 
from human B cells from convalescent patients. It was well tolerated at all doses tested, with no serious 
drug-related severe adverse events (SAEs) reported to date. There are currently multiple ongoing Phase 
3 trials underway for LY-CoV555 for inpatients (NCT04501978) and outpatients (NCT04518410) with 
COVID-19, as well as in nursing home residents and staff (NCT04497987). Additionally a Phase 3 trial of 
combination of LY-CoV555 and LY-CoV016 for participants with mild to moderate COVID-19 Illness 












have shown that treatment was associated with a trend toward decreased hospitalization among 
patients who received any dose of mAb (relative to placebo), as well as a slight decrease in symptom 
severity up until day 6 (but not after). Surprisingly, only the 2,800 mg (medium dose) group in the LY-
CoV555 study resulted in a statistically significant reduction in viral load by day 11 relative to placebo, 
whereas the higher dose (7,000 mg) did not [149]. Despite these confounding results, LY-CoV555 
received emergency used authorization (EUA) for treatment of recently diagnosed COVID-19 patients at 
risk of developing severe disease by the FDA on November 9, 2020. 
Regeneron initiated Phase 1 trial for its REGN-COV2 therapy (a combination of mAbs 
REGN10933 and REGN10987) on 6/10/2020 (NCT04425629, NCT04426695), and is currently in phase 3 
(NCT04452318). REGN-COV2 was granted emergency use authorization for the treatment of early 
COVID-19 by the FDA on November 21, 2020. REGN-COV is not authorized for use for those who are 
hospitalized or require supplemental oxygen therapy. This EUA was based on initial data from the REGN-
COV2 trials that found that treatment appeared to reduce viral load as well as reduce the likelihood of 
COVID-19-related medical visits by 57% through day 29, relative to placebo, but found no apparent 
benefit when administered to patients with more advanced disease [150]. Celltrion initiated a trial for 
their mAb CT-P59 on 6/18/2020 (NCT04525079) and has so far not seen any drug-related serious 
adverse events at any dose tested. Vir Biotechnology and GSK initiated a trial for their mAb VIR-7831 for 
the Early Treatment of Coronavirus Disease 2019 (COVID-19) in non-hospitalized patients on 8/27/2020. 
Many more mAbs isolated from SARS-CoV-2 patients’ B-cells are initiating clinical trials and can be 
followed using the COVID-19 Antibody Therapeutics Tracker website [151].   
A number of companies have advanced or are advancing a single mAb for COVID-19 (e.g. Eli Lilly, 
Celltrion), and others are advancing a cocktail of two mAbs (e.g. Regeneron).  A key distinction between 
single mAb vs. mAb cocktail is the risk of viral escape with mutations such as N439K [149] and Y453F 












escape mutants can be readily generated to each of the individual antibodies tested [137, 152].  In 
contrast, viral escape mutants are not selected in presence of non-competing or partially competing 
mAb cocktails. Thus, the use of a pair of non-competing mAbs may be highly desirable to overcome the 
possibility of viral escape against specific mAbs.  
 
5. Clinical efficacy of mAbs for the treatment or prevention of ARIs 
5.1. Previous antiviral mAb in clinical trial for ARIs 
The efficacy of influenza vaccines are highly variable, and only moderately reduce the rates of 
hospitalization, especially in high risk groups: among adults ≥65, those who receive the flu vaccine, have 
a 14-43% reduced risk of hospitalization relative to unvaccinated patients [153]. Furthermore, there are 
many ARIs for which no vaccine or effective therapies are available, including RSV, MPV, PIV, adenovirus, 
seasonal coronaviruses (e.g. NL63-CoV), rhinoviruses, and others. Collectively, these ARIs affect tens of 
millions each year in the U.S. alone. Given the substantial annual morbidity and mortality caused by 
these ARIs, it is no surprise that significant efforts have been made to develop mAb-based therapeutics 
for respiratory infections [154]. The majority to date have focused on RSV and influenza, which 
represent the two largest areas of unmet medical need among ARIs. 
Unfortunately, nearly all such efforts to develop mAb as therapy for ARIs have been met with 
disappointing results. Some human or humanized mAbs developed as antivirals that have advanced past 
Phase 1 studies include MEDI-8852 (influenza; IC50 ~41-4,050 ng/mL; 750 or 3000 mg) [155, 156], 
MHAA4549 (influenza; IC50 ~195-6,765 ng/mL; 3,600 or 8,400 mg)[44, 157], CR8020 (influenza; IC50 ~9-
500 ng/mL; 30 mg/kg)[158], CT-P27 (influenza; IC50 ~ 15 ug/mL; 10-20 mg/kg)[136], diridavumab 
(influenza; IC50 ~18-2,200 ng/mL; 30 mg/kg)[159, 160], VIS-410 (influenza; IC50 ~30-7,000 ng/mL; 2,000 
or 4,000 mg)[161, 162], Motavizumab (RSV; IC50 ~20 ng/mL; 15 mg/kg [163]), and palivizumab (RSV; IC50 












which supports the anticipated safe use of mAbs against SARS-CoV-2. Unfortunately, they also did not 
show appreciable efficacy as a therapeutic, even when administered at very high doses (e.g. 3,000 mg 
per patient for MEDI-8852 and 8,400 mg per patient for MHAA4549). Only one - palivizumab, also 
known as Synagis® - has received approval as a prophylaxis; however, its modest efficacy and high costs 
have limited its clinical use to only the most severely premature infants. 
 
5.2. Potential mechanisms for prior failures 
Given the immense efforts to advance antiviral mAbs as a treatment for COVID-19, we believe it 
is important to examine why similar efforts to development treatment for other similar ARIs in the past 
have all failed, in order to better guide current development.   
A common feature of all therapeutic antiviral mAbs listed in Table 1  is the universal focus on 
systemic delivery, either by intramuscular (IM), subcutaneous (SC), or intravenous (IV) injections. As 
noted above, SARS-CoV-2, just like other common viruses responsible for ARIs, preferentially infects 
airway epithelium through the apical membrane, and shed progeny viruses back into the airway lumen 
as infection spreads from the URT to the LRT.  This unique pathophysiology implies that therapeutic 
concentrations of mAbs must be achieved in the AM secretions where viruses concentrate in order to 
effectively neutralize viruses that are actively shed into AM and limit the continued spread of the 
infection within the lung. However, non-human primate studies have shown that the concentration of 
mepolizumab in broncheoalveolar lavage fluid (BALF), following IV injection, is ~500-fold lower than the 
concentration of mepolizumab in plasma[166].  Even greater differences in BALF vs. plasma 
concentration were observed in biodistribution studies of motavizumab (anti-RSV mAb) in cynomolgus 
monkeys, where BALF and plasma concentrations of ~100 ng/mL and ~200,000 ng/mL, respectively, 












magnitude difference in BALF vs. plasma levels of palivizumab injected in neonatal lambs (unpublished 
observations).    
The limited concentrations of mAb measured in BALF following IV delivery imply that the failures 
of many antiviral mAb therapies in the past may simply be attributed to a failure in achieving 
therapeutic concentrations of mAb in the lung airways. Indeed, near complete neutralization of viruses 
requires mAb concentrations well in excess of their IC50 (e.g. 5-10-fold excess).  With many of the mAbs 
that were advanced into clinical studies in the past, neutralization potencies were in the low nanomolar 
affinity (i.e. 20-1,000 ng/mL) range.  Thus, in nearly all cases, the mAb dosing was not likely to have 
achieved effective inhibitive concentrations at the site of infection. It should be noted that the mAb 
levels needed to effectively prevent infection by passive immunization may be substantially less than the 
mAb levels needed to treat an active infection, since infections are typically initiated with low titers of 
viruses. Even with the highly inefficient pulmonary distribution of systemically dosed mAb, it may be 
possible to prevent infection by a small number of viruses, as reflected by the immunoprophylactic 
efficacy of palivizumab, motavizumab, and MEDI-8897 in reducing RSV hospitalization in clinical studies 
[168-170].  However, in the context of a much-greater viral load seen in an active, established infection 
of the respiratory tract, much higher levels of mAb are needed to quickly and effectively limit further 
viral spread. This accentuates the need for any COVID-19 mAb therapy to efficiently distribute the 
administered mAb into the lung airways in order to quickly block the progression of the infection from 
the URT and LRT into the deep lung.  
Another likely factor in the poor clinical efficacy of treating ARIs using antiviral mAbs to date is 
the timing of mAb administration into the patients. Infusions are typically done in a hospitalized setting; 
not surprisingly, with most of the previous clinical trials, patients infected with RSV and influenza are 
often given the mAb only as they are hospitalized. By that point, the viral load with many ARIs is already 












through inappropriate bradykinin signaling following depletion of ACE2 [171] or through a feed-forward 
cycle of inflammation driven by IL-6 and other innate mediators [172, 173]. The delayed initiation of 
dosing is further complicated by the potentially slow distribution of systemically dosed therapies into 
the respiratory tract, leading to substantial delays before reaching Cmax in the lung. This effectively 
allows additional time for viruses to replicate and spread, resulting in further inflammation until 
inhibitory concentrations of the drug are finally reached in the lung. For instance, it takes 3 days of 
twice-daily dosing for osteltamivir, an anti-influenza therapeutic, to achieve steady-state drug 
concentrations in the lung [174]. The time it takes mAbs to effectively distribute into the lung after 
systemic administration is unlikely to be any faster.  
 
6. Strategies to overcome past failures  
6.1. Advancing more potent mAb 
mAbs distribute very poorly from the systemic circulation into the lung [175], with only ~1% of 
the intravenously dosed mAb reaching the lung tissue [176].  An obvious way to increase the likelihood 
of efficacy is to improve the neutralization potency (i.e. IC50) of the mAb; assuming the same amount of 
mAb can reach the lung, a more potent mAb will more effectively inhibit viral replication locally in the 
lung than a less potent mAb. The majority of the current anti-SARS-COV-2 mAbs in active preclinical and 
clinical development have exceptional potencies (IC50 values <10 ng/mL range) (Table 1 ). These 
potencies substantially exceed nearly all of the antiviral mAbs that were previously advanced into 
clinical studies and failed, including palivizumab against RSV (Synagis; IC50 ~163-360 ng/mL [163-165]), 
MEDI8852 against influenza (IC50 ~41-4,050 ng/mL [155, 156]), and MHAA4549 against influenza (IC50 
~195-6,765 ng/mL [44, 157]).  Theoretically, assuming the concentrations of these anti-SARS-CoV-2 
mAbs in BALF can reach ~0.1-0.2% of the mAb concentration in plasma, consistent with prior non-












Indeed, ~100 ng/mL mAb concentration in BALF, arising from 200,000 ng/mL concentration in plasma 
[167], would correspond to 10 times greater mAb than an IC50 of 10 ng/mL).  
 While it may seem promising to simply dose more potent mAb to enhance efficacy, it should be 
noted that other antiviral mAbs  with comparable neutralization potency in vitro have been advanced to 
clinical studies only to fail to provide meaningful benefit. For instance, IV infusion of the anti-RSV mAb 
motavizumab (IC50 ~20 ng/mL [163]) was not effective as a treatment for RSV [177].  Indeed, despite 
clear theoretical benefit, the extent to which greater potencies of mAbs can translate to better 
outcomes in the clinical remains unclear.  For instance, there did not appear to be an appreciable 
difference in the prophylactic effectiveness of MEDI-8897 vs. motavizumab in early clinical studies [178, 
179] despite ~5-fold greater neutralization potency [180] and 9-fold better activity in a cotton rat model 
of RSV infection [181].  As it stands, it seems that greater neutralization potency in vitro may not predict 
effectiveness in vivo, as exemplified by an exceptionally potent mAb against Ebola in vitro affording no 
efficacy in vivo despite no evidence of neutralization escape [182]. 
 Another approach is to simply dose more mAb. For instance, in primate studies with 
motavizumab possessing YTE mutations in its Fc that lead to greater quantities of motavizumab in the 
systemic circulation, there appeared to be a comparable increase in motavizumab in the BALF.  
Nevertheless, in vitro studies suggest the rates of IgG transfer across monolayers of primary cultured 
alveolar epithelial cells may be saturated with higher levels of IgG [183]. In Eli Lilly’s double-blind, 
placebo-controlled Phase 2 study evaluating LY-CoV555 at 700 mg, 2800 mg, and 7000 mg injected per 
patient, only the middle dose, but not the highest dose, met its prespecified primary endpoint of change 
from baseline in viral load at Day 11.  Due to the small clinical trial size, it remains to be determined 
whether higher dosing of LY-CoV555 would translate to greater clinical efficacy.  Many ongoing clinical 
studies are similarly testing mAb dosing at levels that greatly exceed what was tested with prior mAb 













6.2. Initiating mAb therapy earlier 
As discussed in Section 2.2.2, SARS-CoV-2 infections initiate in the URT before progressing 
through the LRT to the deep lung.  In severe cases of deep lung infections, a hyperinflammatory milieu 
associated with dramatically increased expression of IL-6, CRP, and other inflammatory markers, is 
associated with worse prognoses [172]. The hyperinflammatory responses frequently trigger acute 
respiratory distress syndrome (ARDS); a recent survey showed that ~33% of hospitalized COVID-19 
patients develop ARDS, ~26% are transferred to the ICU, and ~16% die [184]. By this stage of the 
infection, the positive feedback loop of inflammatory signaling can proceed in the absence of innate 
sensing of viral pathogen-associated molecular patterns [36, 172, 185], as evidenced by the fact that at 
least some patients with critical disease who receive convalescent plasma treatment can fully clear virus 
within 3 days (per RT-PCR), but still experience worsening decompensation and eventually death [186]. 
Inflammation in the deep lung can also can lead to further life-threatening conditions such as organ 
failure, cerebrovascular disease, and sepsis [42], as well as debilitating, life-long pulmonary fibrosis [187, 
188].  These realities highlight the need for early intervention to prevent the spread of infection to the 
LRT prior to the initiation of a hyperinflammatory response by the innate immune system.  
COVID-19 patients are hospitalized due to morbidities associated with the inflammation caused 
by SARS-CoV-2 infections, rather than the presence of the virus itself.  In our opinion, administering 
antiviral mAb to hospitalized patients with LRT infections is akin to turning off the gas supply that fuels a 
raging fire: while undoubtedly important, the rest of the fire (i.e. inflammation) must be put out to save 
the home. Indeed, it is unlikely that, in late stages of infection, antiviral mAb alone can quickly dampen 
the inflammation when administered after the infection reaches this terminal hyperinflammatory phase.  
Earlier treatment also implies there are lower viral titers in the lung at the time of initiating mAb 












to reach the lung before the viruses potentially spread into the LRT. Thus, the ideal antiviral therapy 
should be initiated early during the course infection, as soon as infection can be practically diagnosed, in 
order to prevent the associated pulmonary morbidities associated with infections in the deep lung.  If 
caught early, the fire likely goes out on its own; URT symptoms typically resolve without requiring 
further medical attention. 
Fortunately, this opportunity exists with COVID-19. Several studies have shown that the median 
time from first symptoms to dyspnea and potential hospitalization is another ~5-7 days [40, 41], and ~8-
12 days to ARDS [89]. This underscores a prime window whereby antiviral mAb can be dosed in patients 
after the onset of symptoms, with adequate time for the mAb to prevent the virus from spreading past 
the LRT into the deep lung.  Reflecting the paradigm shift to initiating mAb therapies earlier, Eli Lilly has 
recently completed a Phase 2 clinical trial to determine the safety and efficacy of LY-CoV555 and LY-
CoV016 for treatment of COVID-19 in an outpatient setting (NCT04427501). Eli Lilly announced in an 
interim report that the cohort receiving across all 3 dose groups, there is a hospitalization or ER visits 
incidence rate of 1.7% compared to 6% in the placebo group, despite only the middle dose achieving its 
primary endpoint of viral titer reduction [148].  In parallel, Eli Lilly has started a phase 3 trial to evaluate 
whether LY-CoV555 stops the residents of nursing homes from developing COVID-19, creating 
customized mobile research units to run the clinical trial at nursing homes (NCT04497987). Regeneron is 
also conducting Phase 1/2/3 trials testing the safety and efficacy of antibody cocktail REGN-COV2 in 
infected ambulatory patients (NCT04425629), as well as prevention of infection in asymptomatic 
patients who are household contacts of individuals infected by SARS-CoV-2 (NCT04452318). Both LY-
CoV555 (bamlanivimab) and REGN-COV2 (casirivimab and imdevimab) have received emergency used 
authorization from the FDA to treat recently diagnosed COVID-19 patients in outpatient settings 















6.3. Direct delivery to the lung 
Virtually all mAb therapeutics currently on the market, and notably all antiviral mAb that was 
previously advanced into clinical studies for ARIs and failed, are administered to the systemic circulation 
either via intravenous, subcutaneous or intramuscular injections. The failures of systemically dosed 
antiviral mAb for ARIs is particularly notable, since nearly all antiviral mAbs currently under clinical 
development for COVID-19 are also administered systemically.  As discussed above, systemic mAb 
dosing results in far lower levels of mAb in the lung relative to the overall dose of mAb administered, 
thereby limiting efficacy.  Methods that can deliver greater amounts of mAb more quickly to where the 
viruses are concentrated will likely more effectively limit the spread of SARS-CoV-2 to the deep lung. 
Inhaled delivery of mAb offers a number of distinct advantages over systemic mAb delivery. 
First, unlike systemic dosing, where the concentration of mAb in the lung is usually reduced 500-2,000+ 
fold compared to the concentration in the circulation (see Section 5.2), a much larger fraction of the 
dosed mAb would reach the site where the viruses are concentrated: the AM. In a non-human primate 
study, mAb concentrations in the lung measured by in vivo microdialysis reached 1 μg/mL shortly after 
nebulization [191]; the authors had unexpectedly poor delivery likely due to an incompatible 
mouthpiece. In another macaque study, nebulized IgG, IgA, and IgM in the epithelial fluid of the lung 
reached concentrations between 500 to 1,000 μg/mL immediately after delivery [192]. In this study, 
1.33 mg/mouse of IgG administered by intranasal deposition were required to prevent bacterial 
pneumonia. In a Phase I trial for inhaled omalizumab that was self-administered using a jet nebulizer, for 
the 10 mg dose cohort, 273 to 2,380 μg of omalizumab was estimated to have been delivered to the 
lung [193]. Given the typical neutralization potencies of antiviral mAbs (IC50 in the 10-300 ng/mL 












concentrations that are well in excess of the IC50.  Achieving and sustaining mAb titers above its IC50 
should translate to more effective inhibition of infections in the lung. For instance, in a mouse influenza 
challenge model, neutralizing mAb dosed intranasally achieved superior efficacy than the same mAb 
administered intraperitoneally, even at lower doses, when the treatment is initiated later in the 
infection [194].  Intranasal dosing of neutralizing mAb also reduced the dose of mAb needed in a RSV 
challenge cotton rat model by orders of magnitude; 4 g/ kg of IVIG delivered by i.p injection were 
required to achieve the same level of protection as 0.025 g/kg delivered by intranasal deposition [195].  
Topical delivery of neutralizing mAbs into the lung has effectively suppressed viral replication in other 
animal models [194-196]. 
Another advantage with inhaled delivery of mAb is the time it takes to reach local Cmax.  When 
inhaled, the maximum concentration of mAb in local lung tissues is naturally highest immediately 
following inhalation. In contrast, limited extravasation from systemic circulation into the lung means 
that systemically dosed drugs typically take many hours if not days to reach a local Cmax. Indeed, steady 
state concentrations of osteltamivir in the lung can only be achieve after 3 days of twice-daily dosing 
[174]. Poor biodistribution of mAb into the respiratory tract was reflected by a mouse study showing 
that, whereas 100% of nebulized cetuximab was present in the lung 2 hours after nebulization, only ~1% 
of cetuximab was localized to the lung 2 hours after i.v. injection [176]. Even after 48 hours, nebulization 
leads to a much greater fraction of mAb in the lung (>50-fold excess) compared to the same dose of 
mAb dosed systemically.  
 
6.3.1. Methods for inhaled delivery 
Generally, mAb can be delivered in the lung in two forms: either as micronized dry powder 
aerosol with suitable aerodynamic diameter to enable efficient inhaled delivery through the use of dry 












been used to deliver small drugs into the lungs for asthma and COPD for decades. They are simple to 
use, require no electrical power, and are highly portable. Vectura, in partnership with UCB, previously 
advanced VR942 (an anti-IL13 mAb fragment for treatment of asthma) into Phase 1 and 2 clinical 
studies, demonstrating good safety in the phase I clinical trial (NCT02473939) [197]. More recently, 
Novartis investigated CSJ117, an anti-thymic stromal lymphopoietin antigen binding antibody fragment 
formulated into DPI, in a double-blind, placebo-controlled study in 28 patients with mild, atopic asthma, 
and observed no treatment-emergent serious adverse events [198]. Nevertheless, DPIs also have a 
number of important disadvantages relevant to mAb delivery. First, DPIs result in a large fraction of the 
drug deposited in the mouth and throat and have limited delivery to the upper respiratory tract (i.e. 
sinuses). Second, some patients, particularly elderly and pediatric patients, have trouble using DPIs as 
intended. Finally, the formulation of complex biomacromolecules such as mAb into DPIs require 
extensive development effort, with timelines that may not be compatible with the urgencies needed to 
quickly respond to a pandemic.  For these reasons, ~75% of inhaled therapeutics in clinical development 
have pursued the nebulization of liquid protein preparations [199].  
There are 3 major classes of nebulizers: jet, ultrasonic, and mesh nebulizers; they differ with 
respect to the physical process utilized to generate aerosols, but they typically generate particles in 
the 2 to 5 μM range [200].  For optimal deposition into the conducting lung airways as well as the 
deep lung, the median mass aerodynamic diameter of the droplets should generally be in the 4-5 μm 
range [201-203]. As shown in Figure 5, the distribution of droplet sizes generated from a nebulizer can 
enable effective delivery to all parts of the respiratory tract, from the URT to LRT to the deep lung [204, 
205].  For instance, intrapulmonary deposition of a nebulized radiolabeled drug with median droplet 
diameter of 2.9 μm (89.2% of droplets had a diameter <5μm) ranged from 33-40%, while peripheral lung 
deposition ranged from 17-20%[206]. Similarly, inner lung deposition of radiolabeled nebulized drug 












34.8% deposition was observed in the upper airways and only ~0.99% was exhaled by the patients[207]. 
As high as 80% lung deposition has been achieve with nebulizers that generate particles with average 
diameters of 3 μm [208]. Nebulizers can be operated with additional systems to filter out particles larger 
than the desired size, and in that way increase drug deposition in the targeted lung region[209]. Rapid 
lung deposition of therapeutics can be achieved even with modest lung deposition efficiencies. For 
instance, even with a lung deposition rate of 32%, 43.9 mg of tobramycin could be delivered in 
2.5 minutes with a mesh nebulizer [210]. 
 
Figure 5. Relationship between aerosol diameter and lung deposition predicted by the Model by the International 
Commission on Radiological Protection. Aerosols with diameters >5 μm deposit mainly on the oropharynx, 
whereas particles with sizes <5μm can travel deeper into the lung and deposit in the bronchial/conducting airways 
or reach the alveoli (diameter < 1 μm).  Reproduced with permission of the © ERS 2020: European Respiratory 
Journal 37 (6) 1308-1417; DOI: 10.1183/09031936.00166410 Published 1 June 2011. 
  
 
Jet nebulizers have been successfully used to nebulize protein therapeutics that are FDA-approved, 
namely Pulmozyme®.  In jet nebulizers, a compressed gas, often air, passes through a liquid reservoir 
containing the drug, atomizing the liquid intro primary aerosols. These aerosolized particles are then 












whereas small aerosols of a specific size are carried out by the gas for inhalation. Several cycles of 
aerosolization are required to nebulize the therapeutic, and the repeated recirculation of the aerosols, 
together with the air-liquid interface, and both increase protein aggregation[211].  Aggregated proteins 
in turn could potentially more readily induce anti-drug antibodies (ADA), as was observed with 
omalizumab nebulized using a jet nebulizer [193]. Readers are referred to an excellent review on the 
mechanism of protein aggregation during nebulization[212]. Finally, jet nebulizers typically have 
considerable  “dead volume”; residual mass can be up to 50% of the loaded drug mass[213, 214]. This 
wasted volume would be a significant concern with an expensive complex biological molecule like mAb.  
Ultrasonic nebulizers have been used for pulmonary delivery of a variety of therapeutics.  In 
ultrasonic nebulizers, a piezo-electric crystal at the bottom of the medical reservoir vibrates at 
frequencies between 1 and 3 mHz to generate a geyser that releases aerosols [215]. Small particles are 
collected in the nebulization chamber, while larger particles cycle back into the liquid chamber after 
aggregating or colliding with baffles. Similar to jet nebulizers, droplet recirculation increases aggregation 
of biomolecules [212].  Importantly, ultrasonic nebulizers are generally not suitable for nebulization of 
heat labile biomolecules; excess energy from the ultrasonic vibration is converted into heat, which 
substantially increases the temperature of the liquid reservoir by as much as 20oC[215, 216]which in 
turn leads to aggregation or degradation of the therapeutic. Finally, just like jet nebulizers, ultrasonic 
nebulizers also have large dead volumes as high as 30% [214].  
 
6.3.2. Vibrating mesh nebulizers (VMN) 
VMNs aerosols are formed by pushing a liquid containing the therapeutic molecule through a 
vibrating mesh. The mesh contains conical holes, with the broader end at the liquid interface. Droplets 
are generated in a predictable range of sizes, and the aerodynamic diameter of droplets can be tailored 












nebulizers and passive mesh nebulizers. These devices are small, portable, and can be powered by 
batteries. They achieve up to twice the lung deposition of jet nebulizers, and have residual volumes of 
less than 10% [212, 214]. Recirculation of the liquid containing the therapeutic inside the machine is not 
necessary, which is a major concern in jet and ultrasonic nebulizers since it can lead to protein 
aggregation and denaturation. Indeed, VMNs nebulize mAbs with far fewer aggregates [218]. For 
instance, during preclinical development of ALX-0171, a trivalent nanobody for RSV, it was observed that 
jet nebulizers had up to 40% increase in high-molecular weight species, whereas the APIXNEB VMN only 
produced a 2-3% increase [219].   
Given these advantages, it is not surprising that VMN have become the preferred method for 
nebulization of therapeutics by the pharmaceutical industry and clinicians since 2004; mesh nebulizers 
have been used in 60% of registered clinical trials in the USA and EU, from 2006 to 2016. Jet nebulizers 
have only been used in 36% of the trials in the same time frame[208]. The FDA approved the PARI 
eRapid® VMN for nebulized delivery of Pulmozyme® in 2015; compared to jet nebulizers, the eRapid® 
VMN showed equal efficacy and safety, 73% shorter nebulization times, and greater patient 
satisfaction[220]. We refer readers to excellent articles detailing the advantages of VMN over other 
nebulizers [199, 208, 214, 221]. 
The integration of breath-activated or smart functions into VMN has further improved their 
efficiency. One such technology is Adaptive aerosol delivery (AAD®). This technology that was developed 
to predict the patient’s own inhalation pattern to optimize the time for aerosol delivery [222]. This 
decreases the amount of drug wasted during exhalation, which is a problem with jet nebulizers due to 
their continued flow, and reduces variations in lung deposition [221]. Some of the latest VMD with AAD 
includes the I-neb AAD System[223], the AKITA® system [224] and Pulmonary Drug Delivery 
Systems[178].  These devices improve the overall deposition efficiency from ~60% with conventional 












Few inhalable monoclonal antibodies have been tested or are being tested in clinical trials [199]; 
however, evidence of successful antibody nebulization by VMN is available from various preclinical 
studies. For instance, an anti-IL13 neutralizing antibody was nebulized with eFlow® vibrating mesh 
nebulizer. It retained high affinity and potency following nebulization, and no aggregation or 
degradation was observed [226]. The antibody was tested in a model of chronic asthma in cynomolgus 
macaques, where it showed it can inhibit lung inflammation due to allergen exposure [227]. 
Nebulization and deposition of IgGs, IgAs, and IgMs into the lungs of rats and non-human primates by 
eFlow® mesh nebulizer was examined by Vonarburg [192]. For all their Ig formulations, >69% of their 
particles had a diameter smaller than 5 μm. They also observed that IgG, IgA, and IgM maintain their 
structural integrity, did not induce aggregation vs. unnebulized controls, and retain their activity after 
nebulization, as shown in Table 2. This study demonstrated that even large molecules such as IgM (970 
kDa) can be nebulized by VMN. Respaud et al effectively nebulized two mAbs, an IgG1 and an IgG4, 
using Omron, PARI eFlow®, and Aerogen Solo mesh nebulizers [228]. Protein formulation, such as the 
presence of surfactants and protein concentration, can be optimized to further reduce mAb 
aggregation. 
Table 2. Physical characterization of immunoglobulin aerosol generated with a vibrating mesh nebulizer. Ig formulations were 
analyzed by size exclusion chromatography after nebulization. Table adapted from [192] 
Formulation Condition 
High molecular 



















































Finally, studies of the nebulized delivery of a variety of biologics have generally shown them to 












delivery of Omalizumab [193], Pulmozyme®[229], DAS-181[99], SNG001 (interpheron beta-1a) [230], 
Alpha-1 antitrypsin [231], Molgramostim [232], or the ALX-0171 nanobody (including in adults with 
hypersensitive airways [219]). Both inhalable DAS181 (NCT04324489) and SNG001 (NCT04385095) are 
currently being evaluated in phase I/II clinical trials for COVID-19. These results underscore that 
inhalation of human mAb using VMNs is a potentially safe and efficacious route of delivering mAbs into 
the lung.  
  
7. Conclusion and Perspectives 
The various infections that comprise ARIs have long been a public health, and occasionally, 
global health challenge. While the COVID-19 pandemic has brought about sufferings on a societal and 
economic scale rarely seen in the past, it has also catalyzed more efforts across the entire medical and 
scientific spectrum in a race against time to advance effective interventions to the infection dwarfing 
even those for HIV and other important infections.  With the integration of the latest advances in mAb 
discovery, large scale mAb manufacturing and drug delivery technologies, we believe all the tools are in 
place to enable mAbs to serve as effective therapeutic intervention for COVID-19, with opportunities 
particularly in pulmonary delivery and harnessing mucosal effector functions of mAb.  The lessons 
learned will likely provide an important platform for the scientific community to better develop 
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